Frank X. Leonard - 27 Feb 2024 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
EVP, Pres., Novocure Oncology
Signature
Steven Robbins, as attorney in fact for Leonard, Frank X.
Issuer symbol
NVCR
Transactions as of
27 Feb 2024
Net transactions value
+$4,181,586
Form type
4
Filing time
29 Feb 2024, 16:38:56 UTC
Previous filing
12 Jan 2024
Next filing
05 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $1,666,659 +102,249 +164% $16.30 164,695 27 Feb 2024 Direct F1
transaction NVCR Ordinary Shares Sale $33,545 -2,078 -1.3% $16.14 162,617 28 Feb 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVCR Stock Options (Right to buy) Award $2,548,472 +156,348 $16.30 156,348 27 Feb 2024 Ordinary Shares 156,348 $16.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3 Options to buy 156,348 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.